Sponsored by North American Center for Continuing Medical Education, LLC

Activity Details

Intended Learners

This activity is designed for orthopedists, including orthopedic physicians and surgeons.

Learning Objectives

After completing this activity, participants will be able to:

• Discuss the pathophysiology of osteoporosis
• Identify targets for current and future osteoporosis therapy
• Outline the benefits and limitations of anti-resorptive and anabolic agents for the treatment of osteoporosis
• Implement guideline-based practices for initiating aggressive management of high-risk patients with a previous fracture

Activity Overview

This on-demand webcast is available with synchronized slides and audio.

To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online, participants may immediately print their documentation of credit.

This educational activity is a knowledge-based activity.

For questions regarding this educational activity, please email info@naccme.com.

Hardware/Software Requirements

OpenCME requires minimum browser versions of Microsoft Internet Explorer® 7, Mozilla Firefox 3, Safari 4 or Chrome 10. Certain activities may require additional software to view.
That software may be: Adobe Reader®, and Adobe® Flash® Player.

Accreditation

In support of improving patient care, North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

NACCME designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Independent Clinical Reviewer: Gloria A. Bachmann, MD, UNDNJ-Robert Wood Johnson Medical School, Associate Dean of Women’s Health, Interim Chair—OB/GYN, New Brunswick, New Jersey

Planning Committee

The planning committee comprises Gloria Bachmann, MD, and E. Michael Lewiecki, MD, FACP, FACE; and Stephen Chavez, Stacey Ohana, Randy Robbin, Lynn Rubin, and John Savage, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:
Dr. Bachmann: Grant/research support—Barr Laboratories, Bayer, Boehringer Ingelheim, Duramed, Endoceutics, Ferring Pharmaceuticals, Johnson & Johnson, Merck & Co. Inc, Novartis, Novo Nordisk, Pfizer, QuatRx Pharmaceuticals, Teva; Consultant—Astellas, Barr Laboratories, Boehringer Ingelheim, Johnson & Johnson, Merck & Co, Inc, Novartis, Novo Nordisk, Ospemifene Steering Committee, Pfizer, Proctor & Gamble (now Warner Chilcott), Solvay; Scientific Advisor—Astellas, Barr Laboratories, Boehringer Ingelheim, Johnson & Johnson, Merck & Co, Inc, Novartis, Novo Nordisk, Ospemifene Steering Committee, Pfizer, Proctor & Gamble (now Warner Chilcott), Solvay; Promotional speakers bureau—Astellas, Barr Laboratories, Boehringer Ingelheim, Johnson & Johnson, Merck & Co, Inc, Novartis, Novo Nordisk, Ospemifene Steering Committee, Pfizer, Proctor & Gamble (now Warner Chilcott), Solvay

Dr. Lewiecki: Grant/research support (principal investigator, funding to New Mexico Clinical Research & Osteoporosis Center)—Amgen, Eli Lilly and Company, Genentech, GlaxoSmithKline, Merck, Novartis, Warner Chilcott; Consultant—GlaxoSmithKline; Scientific advisory board—Amgen, Eli Lilly, Genentech, Merck, Novartis; Promotional speakers bureau—Amgen, Eli Lilly, Genentech, Novartis

Mr. Chavez, Ms. Ohana, Mr. Robbin, Ms. Rubin, and Mr. Savage have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty has disclosed that no off-label/unapproved uses of drugs and/or devices will be discussed.

This continuing education activity includes device brand names for participant clarity purposes only. No product promotion or recommendation should be inferred.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2012 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.

Grant Support

Supported by an independent educational grant from Eli Lilly and Company.